Akebia Therapeutics (AKBA) Return on Sales (2017 - 2026)

Akebia Therapeutics (AKBA) has 10 years of Return on Sales data on file, last reported at 0.0% in Q1 2026.

• On a quarterly basis, Return on Sales changed 0.0% year-over-year to 0.0% in Q1 2026; TTM through Mar 2026 was 0.0%, a 0.0% change from a year earlier, with the FY2025 full-year figure at 0.0%, changed 0.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.0%, up from 0.0% in the prior quarter.
• Over the last five years, Return on Sales for AKBA reached as high as 0.0% in Q2 2022 and fell as low as 8.19% in Q1 2022.
• Historically, Return on Sales has averaged 0.48% across 5 years, with a median of 0.0% in 2023.
• Across the five-year window, Return on Sales sank 818 bps in 2022 and jumped 819 bps in 2023, its largest moves.
• Year by year, Return on Sales stood at 0.0% in 2022, then soared by 115 bps to 0.0% in 2023, then slumped by 4589 bps to 0.0% in 2024, then jumped by 57 bps to 0.0% in 2025, then gained by 20 bps to 0.0% in 2026.
• Per Business Quant data, the three most recent Return on Sales figures were 0.0% in Q1 2026, 0.0% in Q4 2025, and 0.0% in Q3 2025.